ArticleAntimicrobial agents and chemotherapy2020
ARGONAUT II Study of the
Abstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Resistance to Plazomicin: An Analysis of the Evidence from In Vitro Antimicrobial Susceptibility Studies.Antibiotics (Basel, Switzerland) · 2026Review
- Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens.Frontiers in microbiology · 2025Review
- ARGONAUT-IV: susceptibility of carbapenemase-producingAntimicrobial agents and chemotherapy · 2024Article
- ARGONAUT-III and -V: susceptibility of carbapenem-resistantAntimicrobial agents and chemotherapy · 2024Article
- In vitro activity of plazomicin and other aminoglycosides against Klebsiella pneumoniae multidrug-resistant strains.The Journal of antibiotics · 2024Article
- Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales.Journal of clinical microbiology · 2022Article
- Present and Future Perspectives on Therapeutic Options for Carbapenemase-ProducingMicroorganisms · 2021Review
- An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria.Journal of clinical medicine · 2021Review
- Article
- Plazomicin in multidrug-resistant complicated urinary tract infections: a scoping review.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Michael R JacobsDepartment of Pathology, Case Western Reserve University, Cleveland, Ohio, USA mrj6@case.edu robert.bonomo@va.gov.
Caryn E GoodDepartment of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
Andrea M HujerDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Ayman M AbdelhamedDepartment of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
Daniel D RhoadsDepartment of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
Kristine M HujerDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Susan D RudinDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
T Nicholas DomitrovicDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Lynn E ConnollyAchaogen, Inc., South San Francisco, California, USA.
Kevin M KrauseAchaogen, Inc., South San Francisco, California, USA.
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6344-4141
Cesar A AriasDivision of Infectious Diseases, McGovern School of Medicine at Houston, Houston, Texas, USA.
Barry N KreiswirthHackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Laura J RojasDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Roshan D'SouzaJ. Craig Venter Institute, Rockville, Maryland, USA.
Richard C WhiteJ. Craig Venter Institute, Rockville, Maryland, USA.
Lauren M BrinkacJ. Craig Venter Institute, Rockville, Maryland, USA.
Kevin NguyenJ. Craig Venter Institute, Rockville, Maryland, USA.
Indresh SinghJ. Craig Venter Institute, Rockville, Maryland, USA.
Derrick E FoutsJ. Craig Venter Institute, Rockville, Maryland, USA.ORCID 0000-0003-4323-7668
David van DuinDivision of Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0003-4784-3227
Robert A BonomoDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA mrj6@case.edu robert.bonomo@va.gov.
Antibacterial Resistance Leadership Group
Funding
Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MThe J. Craig Venter Institute Genome Center for Infectious DiseasesU19AI110819 · NIAID · J. CRAIG VENTER INSTITUTE, INC. · PI NIERMAN, WILLIAM CHARLES · 2014 to 2018
$29.7MThe molecular basis of the epidemic blaKPC gene KlebsiellaR01AI090155 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KREISWIRTH, BARRY NEAL · 2011 to 2021
$7.2MUnderstanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MThe LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7MMolecular basis of the cefazolin inoculum effectR21AI143229 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2019 to 2020
$442kThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974NCATS NIH HHS UL1 TR001863NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI090155NIAID NIH HHS R01 AI100560NIAID NIH HHS R01 AI134637NIAID NIH HHS R21 AI143229NIAID NIH HHS U19 AI110819NIAID NIH HHS UM1 AI104681
Abstract
Plazomicin was tested against 697 recently acquired carbapenem-resistant
Indexed as
AdultAgedAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenem-Resistant EnterobacteriaceaeDrug Resistance, BacterialFemaleHumansKlebsiella pneumoniaeMaleMethyltransferasesMicrobial Sensitivity TestsMiddle AgedSisomicinUnited StatesAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseMethyltransferasesplazomicinSisomicinantibiotic resistancecarbapenemaseKlebsiellaplazomicin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.